Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study

彭布罗利珠单抗 医学 内科学 吉西他滨 胆道癌 化疗 肿瘤科 乙型肝炎病毒 安慰剂 不利影响 癌症 乙型肝炎 胆道 胃肠病学 临床试验 胰腺癌 癌 脱氧胞苷 临床研究阶段 护理标准 免疫疗法 病毒 外科 安全概况
作者
Stephen Lam Chan,Thomas C. C. Yau,R. K. Kelley,Richard S. Finn,Changhoon Yoo,Junji Furuse,Zhenggang Ren,Heinz‐Josef Klümpen,M. Ozaka,Uwe Pelzer,Çağatay Arslan,Joon Oh Park,Julien Edeline,Juan W. Valle,M. Ueno,Arndt Vogel,Liis Starkopf,Usha Malhotra,Abby B. Siegel,Shukui Qin
出处
期刊:Cancer research communications [American Association for Cancer Research]
卷期号:6 (3): 577-584 被引量:2
标识
DOI:10.1158/2767-9764.crc-25-0633
摘要

PURPOSE: In the randomized phase 3 KEYNOTE-966 trial, first-line pembrolizumab plus chemotherapy significantly improved overall survival (OS) versus placebo plus chemotherapy for participants with advanced biliary tract cancer (BTC). This post hoc analysis investigated whether hepatitis B virus (HBV) infection affected the efficacy and safety of pembrolizumab plus chemotherapy. PATIENTS AND METHODS: Eligible participants had histologically confirmed extrahepatic or intrahepatic cholangiocarcinoma or gallbladder cancer, unresectable locally advanced or metastatic disease measurable per RECIST v1.1, known HBV and HCV status (including active HBV), and Eastern Cooperative Oncology Group performance status 0 or 1. Participants were randomly assigned 1:1 to intravenous pembrolizumab 200 mg or placebo every 3 weeks for ≤35 cycles plus gemcitabine and cisplatin. HBV-positive participants were monitored for HBV reactivation, and antiviral therapy was required for chronic HBV infection. The primary end point was OS. RESULTS: The intention-to-treat population comprised 1,069 participants (533, pembrolizumab group; 536, placebo group). The median time from randomization to data cutoff (November 14, 2023) was 36.6 months (range, 29.2-49.4). Among 329 HBV-positive participants (30.8%), 30 had chronic and 299 had clinically resolved HBV. The OS HR was 0.87 [95% confidence interval (CI), 0.69-1.10] with pembrolizumab versus placebo for the HBV-positive subgroup and 0.85 (95% CI, 0.73-0.99) for the HBV-negative subgroup. Safety was consistent between the subgroups. Eight participants had HBV reactivation (5, pembrolizumab group; 3, placebo group), and no cases of HBV-associated hepatitis occurred in either group. CONCLUSIONS: Efficacy and safety outcomes were consistent between HBV-positive and HBV-negative participants receiving first-line pembrolizumab compared with placebo plus gemcitabine and cisplatin. SIGNIFICANCE: Chronic HBV infection is a risk factor for BTC, potentially affecting the effectiveness of BTC treatment. In this study, treatment outcomes in participants who received first-line pembrolizumab plus gemcitabine and cisplatin for advanced BTC treatment were consistent regardless of HBV infection status.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
aaa八角锋哥完成签到,获得积分10
1秒前
Zhuxiaole完成签到,获得积分10
2秒前
2秒前
内向晓旋发布了新的文献求助10
2秒前
CUCUMBER完成签到,获得积分10
2秒前
obtu发布了新的文献求助10
2秒前
科研通AI65的应助被小浪矢采纳,获得10
3秒前
sasakiki发布了新的文献求助10
4秒前
Brave发布了新的文献求助10
5秒前
谦让衫完成签到 ,获得积分10
5秒前
5秒前
江子川发布了新的文献求助10
5秒前
7秒前
Orange的应助被zzj采纳,获得10
7秒前
科研通AI6.2的应助被匆匆采纳,获得10
7秒前
7秒前
8秒前
笨笨卡卡西完成签到,获得积分10
8秒前
9秒前
CipherSage的应助被研友_89e5G8采纳,获得10
9秒前
9秒前
9秒前
科研通AI65的应助被ge_jn采纳,获得10
10秒前
鹭江完成签到,获得积分10
10秒前
soory完成签到,获得积分10
10秒前
11秒前
江子川发布了新的文献求助10
11秒前
11秒前
江子川发布了新的文献求助10
11秒前
研友_VZG7GZ的应助被米兰小铁匠采纳,获得10
11秒前
tso关注了科研通微信公众号
11秒前
江子川发布了新的文献求助10
11秒前
aaaaasdsaf发布了新的文献求助10
12秒前
小熊维尼发布了新的文献求助20
12秒前
慕子默完成签到,获得积分10
13秒前
13秒前
左西完成签到 ,获得积分10
14秒前
江子川发布了新的文献求助10
14秒前
周华健发布了新的文献求助10
14秒前
zj发布了新的文献求助10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192250
求助须知:如何正确求助?哪些是违规求助? 9578881
关于积分的说明 21862513
捐赠科研通 7791814
什么是DOI,文献DOI怎么找? 3436868
关于科研通互助平台的介绍 2560584
邀请新用户注册赠送积分活动 2483698